433 related articles for article (PubMed ID: 30764769)
1. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection.
Stalenhoef JE; van Nieuwkoop C; Wilson DC; van der Starre WE; van der Reijden TJK; Delfos NM; Leyten EMS; Koster T; Ablij HC; van 't Wout JJW; van Dissel JT
BMC Infect Dis; 2019 Feb; 19(1):161. PubMed ID: 30764769
[TBL] [Abstract][Full Text] [Related]
2. Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection.
Stalenhoef JE; van Nieuwkoop C; Wilson DC; van der Starre WE; Delfos NM; Leyten EMS; Koster T; Ablij HC; Van't Wout JJW; van Dissel JT
J Infect; 2018 Jul; 77(1):18-24. PubMed ID: 29807091
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection.
van der Starre WE; Zunder SM; Vollaard AM; van Nieuwkoop C; Stalenhoef JE; Delfos NM; Van't Wout JW; Spelt IC; Blom JW; Leyten EM; Koster T; Ablij HC; van Dissel JT
Clin Microbiol Infect; 2014 Oct; 20(10):1048-54. PubMed ID: 25039648
[TBL] [Abstract][Full Text] [Related]
4. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.
van Nieuwkoop C; van der Starre WE; Stalenhoef JE; van Aartrijk AM; van der Reijden TJ; Vollaard AM; Delfos NM; van 't Wout JW; Blom JW; Spelt IC; Leyten EM; Koster T; Ablij HC; van der Beek MT; Knol MJ; van Dissel JT
BMC Med; 2017 Apr; 15(1):70. PubMed ID: 28366170
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
6. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
[TBL] [Abstract][Full Text] [Related]
7. Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections--'triple p in uti': study protocol for a randomized controlled trial.
Drozdov D; Thomer A; Meili M; Schwarz S; Kouegbe RB; Regez K; Guglielmetti M; Schild U; Conca A; Schäfer P; Reutlinger B; Ottiger C; Buchkremer F; Litke A; Schuetz P; Huber A; Bürgi U; Fux CA; Bock A; Müller B; Albrich WC;
Trials; 2013 Mar; 14():84. PubMed ID: 23522152
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
[TBL] [Abstract][Full Text] [Related]
9. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P;
Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917
[TBL] [Abstract][Full Text] [Related]
10. MR- proADM to detect specific types of organ failure in infection.
Andrés C; Andaluz-Ojeda D; Cicuendez R; Nogales L; Martín S; Martin-Fernandez M; Almansa R; Calvo D; Esteban-Velasco MC; Vaquero-Roncero LM; Ríos-Llorente A; Sanchez-Barrado E; Muñoz-Bellvís L; Aldecoa C; Bermejo-Martin JF
Eur J Clin Invest; 2020 Jun; 50(6):e13246. PubMed ID: 32307701
[TBL] [Abstract][Full Text] [Related]
11. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
[TBL] [Abstract][Full Text] [Related]
12. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
13. Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.
Viaggi B; Poole D; Tujjar O; Marchiani S; Ognibene A; Finazzi S
PLoS One; 2018; 13(8):e0201491. PubMed ID: 30102716
[TBL] [Abstract][Full Text] [Related]
14. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*.
Debiane L; Hachem RY; Al Wohoush I; Shomali W; Bahu RR; Jiang Y; Chaftari AM; Jabbour J; Al Shuaibi M; Hanania A; Pravinkumar SE; Schuetz P; Raad I
Crit Care Med; 2014 Dec; 42(12):2500-7. PubMed ID: 25083975
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
16. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
18. MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children.
Peñalver Penedo R; Rupérez Lucas M; Álvarez-Sala Walther LA; Torregrosa Benavent A; Casas Losada ML; Bañuelos Andrio L; Rebolledo Poves AB; Bueno Campaña M
BMC Pediatr; 2021 Jun; 21(1):292. PubMed ID: 34187408
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study).
van der Does Y; Limper M; Jie KE; Schuit SCE; Jansen H; Pernot N; van Rosmalen J; Poley MJ; Ramakers C; Patka P; van Gorp ECM; Rood PPM
Clin Microbiol Infect; 2018 Dec; 24(12):1282-1289. PubMed ID: 29870855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
